伊沙妥昔单抗治疗同种异体造血细胞移植后的红细胞移植延迟。

IF 0.7 Q4 HEMATOLOGY
Case Reports in Hematology Pub Date : 2024-08-30 eCollection Date: 2024-01-01 DOI:10.1155/2024/5790011
Mary Nauffal, Stephen Eng, Andrew Lin, Alexander Chan, Kathryn Mazzerella, Sergio Giralt, Miguel-Angel Perales, Boglarka Gyurkocza
{"title":"伊沙妥昔单抗治疗同种异体造血细胞移植后的红细胞移植延迟。","authors":"Mary Nauffal, Stephen Eng, Andrew Lin, Alexander Chan, Kathryn Mazzerella, Sergio Giralt, Miguel-Angel Perales, Boglarka Gyurkocza","doi":"10.1155/2024/5790011","DOIUrl":null,"url":null,"abstract":"<p><p>Isatuximab is an IgG1<i>κ</i>-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuximab. Our patient was a 75-year-old female with acute myeloid leukemia who received an HLA-B antigen mismatched, unrelated peripheral blood stem cell transplant with a major ABO incompatibility (blood group A+ in the donor and blood group O+ in the recipient). The patient developed persistent red cell aplasia and anti-A antibodies for more than 500 days from transplant. She received therapy with rituximab, bortezomib, prednisone, and darbepoetin alfa with partial to no response. After repeated insurance denials for daratumumab, isatuximab was obtained from the manufacturer through their CareASSIST program. Following the completion of 2 cycles of isatuximab (8 doses), significant and sustained red cell recovery was observed.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2024 ","pages":"5790011"},"PeriodicalIF":0.7000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379505/pdf/","citationCount":"0","resultStr":"{\"title\":\"Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation.\",\"authors\":\"Mary Nauffal, Stephen Eng, Andrew Lin, Alexander Chan, Kathryn Mazzerella, Sergio Giralt, Miguel-Angel Perales, Boglarka Gyurkocza\",\"doi\":\"10.1155/2024/5790011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Isatuximab is an IgG1<i>κ</i>-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuximab. Our patient was a 75-year-old female with acute myeloid leukemia who received an HLA-B antigen mismatched, unrelated peripheral blood stem cell transplant with a major ABO incompatibility (blood group A+ in the donor and blood group O+ in the recipient). The patient developed persistent red cell aplasia and anti-A antibodies for more than 500 days from transplant. She received therapy with rituximab, bortezomib, prednisone, and darbepoetin alfa with partial to no response. After repeated insurance denials for daratumumab, isatuximab was obtained from the manufacturer through their CareASSIST program. Following the completion of 2 cycles of isatuximab (8 doses), significant and sustained red cell recovery was observed.</p>\",\"PeriodicalId\":46307,\"journal\":{\"name\":\"Case Reports in Hematology\",\"volume\":\"2024 \",\"pages\":\"5790011\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379505/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/5790011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/5790011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

伊沙妥昔单抗是一种抗CD38的IgG1κ衍生单克隆抗体,已被批准用于治疗成年多发性骨髓瘤患者。在这里,我们描述了使用伊沙妥昔单抗成功治疗ABO不匹配异基因干细胞移植后的难治性纯红细胞再生不良病例。我们的患者是一名75岁的女性急性髓性白血病患者,她接受了HLA-B抗原不匹配的非亲缘外周血干细胞移植,并伴有严重的ABO不相容(供者血型为A+,受者血型为O+)。移植后500多天,患者出现持续性红细胞再生不良和抗A抗体。她接受了利妥昔单抗、硼替佐米、泼尼松和达贝苗 alfa 等药物治疗,但效果不佳。在达拉曲单抗多次被保险公司拒绝后,她通过 CareASSIST 计划从生产商处获得了伊沙妥昔单抗。在完成两个周期的伊沙妥昔单抗治疗(8 个剂量)后,观察到红细胞明显而持续地恢复。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation.

Isatuximab is an IgG1κ-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuximab. Our patient was a 75-year-old female with acute myeloid leukemia who received an HLA-B antigen mismatched, unrelated peripheral blood stem cell transplant with a major ABO incompatibility (blood group A+ in the donor and blood group O+ in the recipient). The patient developed persistent red cell aplasia and anti-A antibodies for more than 500 days from transplant. She received therapy with rituximab, bortezomib, prednisone, and darbepoetin alfa with partial to no response. After repeated insurance denials for daratumumab, isatuximab was obtained from the manufacturer through their CareASSIST program. Following the completion of 2 cycles of isatuximab (8 doses), significant and sustained red cell recovery was observed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
51
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信